Clinical Lessons from the Global Aortic VIVID Registry – Optimizing Procedural Outcomes

Status Update of the TAVR UNLOAD Trial – Moderate AS Patients with Reduced Ejection Fraction and Heart Failure

Putting It All Together: A Proposed New Staging Classification for Patients with Aortic Stenosis

Who Should be Treated? The Role of Biomarkers in Patient Selection and Procedure Optimization

Who Should be Treated? The Role of Imaging Guidance in Patient Selection

Rationale for Treating SASS and Update of the EARLY-TAVR Trial

My Crystal Ball - Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis Once the ‘Cycle’ of Low-Risk Studies is Completed

The Case for TAVR in “Low-Risk” Patients: Rationale, Current Data, Clinical Trends, and Updates from the Ongoing Clinical Trials

NO – The Data are Inconclusive and the Costs are Prohibitive!

YES – Review of ALL the Data and Common Sense Tell the Story!